Not a healthcare professional? Go to the patient or caregiver website.

PREMARIN® VAGINAL CREAM Clinical Pharmacology (conjugated estrogens)


12.1 Mechanism of Action

Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.

The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, which is secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate-conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.

Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue.

Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and FSH, through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these gonadotropins seen in postmenopausal women.

12.2 Pharmacodynamics

Currently, there are no pharmacodynamic data known for PREMARIN Vaginal Cream.

12.3 Pharmacokinetics


Conjugated estrogens are water soluble and are well-absorbed through the skin, mucous membranes, and the gastrointestinal (GI) tract. The vaginal delivery of estrogens circumvents first-pass metabolism.

A bioavailability study was conducted in 24 postmenopausal women with atrophic vaginitis. The mean (SD) pharmacokinetic parameters for unconjugated estrone, unconjugated estradiol, total estrone, total estradiol and total equilin following 7 once-daily doses of PREMARIN Vaginal Cream 0.5 g is shown in Table 2.

Table 2: Mean ± SD Pharmacokinetic Parameters of PREMARIN Following Daily Administration (7 Days) of PREMARIN Vaginal Cream 0.5 g in 24 Postmenopausal Women
Pharmacokinetic Profiles of Unconjugated Estrogens
PREMARIN Vaginal Cream 0.5 g
PK Parameters
Arithmetic Mean ± SD
Estrone42.0 ± 13.97.4 ± 6.2826 ± 295
Baseline-adjusted estrone21.9 ± 13.17.4 ± 6.2365 ± 255
Estradiol12.8 ± 16.68.5 ± 6.2231 ± 285
Baseline-adjusted estradiol9.14 ± 14.78.5 ± 6.2161 ± 252
Pharmacokinetic Profiles of Conjugated Estrogens
PREMARIN Vaginal Cream 0.5 g
PK Parameters
Arithmetic Mean ± SD
Total estrone0.60 ± 0.326.0 ± 4.09.75 ± 4.99
Baseline-adjusted total estrone0.40 ± 0.286.0 ± 4.05.79 ± 3.7
Total estradiol0.04 ± 0.047.7 ± 5.90.70 ± 0.42
Baseline-adjusted total estradiol0.04 ± 0.047.7 ± 6.00.49 ± 0.38
Total equilin0.12 ± 0.156.1 ± 4.73.09 ± 1.37


The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentration in the sex hormone target organs. Estrogens circulate in the blood largely bound to SHBG and albumin.


Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant portion of the circulating estrogens exists as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens.


Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates.

Use in Specific Populations

No pharmacokinetic studies were conducted in specific populations, including patients with renal or hepatic impairment.

Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No